High Serum Vitamin B12 Levels Associated with C-Reactive Protein in Older Patients with Cancer.

C-reactive protein Early death High serum vitamin B12 levels Older patients with cancer Unplanned hospitalization

Journal

The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837

Informations de publication

Date de publication:
12 2020
Historique:
received: 21 11 2019
accepted: 17 07 2020
pubmed: 4 8 2020
medline: 22 6 2021
entrez: 4 8 2020
Statut: ppublish

Résumé

A Comprehensive Geriatric Assessment (CGA) has been proposed to assess prognosis and to adapt oncological care in older patients with cancer. However, few biological markers are incorporated in the CGA. This comparative study on older patients with cancer was realized before final therapeutic decision and during a CGA that included biological markers. Our objective study was to know if the serum vitamin B12-C-reactive protein index (BCI) can help to estimate early death and unplanned hospitalization. Associations between BCI and unplanned hospitalization or mortality were analyzed using ordered multivariate logistic regression. We included 621 older cancer adults in outpatient care with a median age of 81 years (range, 70-98 years) from September 2015 to May 2018. In this study, 5.6% of patients died within 3 months, 8.8% had unplanned hospitalization within 1 month, and 11.4% had unplanned hospitalization within 3 months. Hypercobalaminemia was present in 83 patients (13.4%), and 34 patients (5.5%) had BCI >40,000. According to the multivariate analysis, BCI was a prognostic factor of mortality within 3 months and unplanned hospitalizations at 1 and 3 months. Impaired activities of daily living (ADL) and palliative care were also risk factors for mortality within 3 months. Impaired instrumental ADL, low albumin level, and palliative care were risk factors for unplanned hospitalization at 1 month. BCI could be routinely added to the CGA process, as part of a pretreatment workup, in order to assess more precisely the frailties and to adapt oncological care in older patients treated for cancer. Aging comes with an increase of frailties and comorbidities. To identify frailties in older patients with cancer, this study used a Comprehensive Geriatric Assessment, which allowed for the adaptation of each treatment plan in accordance with the individual needs of the patients. However, biological characteristics were not included in this assessment. This study showed that hypercobalaminemia and vitamin B12 -C-reactive protein index may be potential markers for cancer with poor prognosis, particularly in the older population. These biological markers can be used in geriatric oncology and general medicine.

Sections du résumé

BACKGROUND
A Comprehensive Geriatric Assessment (CGA) has been proposed to assess prognosis and to adapt oncological care in older patients with cancer. However, few biological markers are incorporated in the CGA.
METHODS
This comparative study on older patients with cancer was realized before final therapeutic decision and during a CGA that included biological markers. Our objective study was to know if the serum vitamin B12-C-reactive protein index (BCI) can help to estimate early death and unplanned hospitalization. Associations between BCI and unplanned hospitalization or mortality were analyzed using ordered multivariate logistic regression.
FINDINGS
We included 621 older cancer adults in outpatient care with a median age of 81 years (range, 70-98 years) from September 2015 to May 2018. In this study, 5.6% of patients died within 3 months, 8.8% had unplanned hospitalization within 1 month, and 11.4% had unplanned hospitalization within 3 months. Hypercobalaminemia was present in 83 patients (13.4%), and 34 patients (5.5%) had BCI >40,000. According to the multivariate analysis, BCI was a prognostic factor of mortality within 3 months and unplanned hospitalizations at 1 and 3 months. Impaired activities of daily living (ADL) and palliative care were also risk factors for mortality within 3 months. Impaired instrumental ADL, low albumin level, and palliative care were risk factors for unplanned hospitalization at 1 month.
INTERPRETATION
BCI could be routinely added to the CGA process, as part of a pretreatment workup, in order to assess more precisely the frailties and to adapt oncological care in older patients treated for cancer.
IMPLICATIONS FOR PRACTICE
Aging comes with an increase of frailties and comorbidities. To identify frailties in older patients with cancer, this study used a Comprehensive Geriatric Assessment, which allowed for the adaptation of each treatment plan in accordance with the individual needs of the patients. However, biological characteristics were not included in this assessment. This study showed that hypercobalaminemia and vitamin B12 -C-reactive protein index may be potential markers for cancer with poor prognosis, particularly in the older population. These biological markers can be used in geriatric oncology and general medicine.

Identifiants

pubmed: 32745312
doi: 10.1634/theoncologist.2019-0894
pmc: PMC8108056
doi:

Substances chimiques

C-Reactive Protein 9007-41-4
Vitamin B 12 P6YC3EG204

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1980-e1989

Informations de copyright

© 2020 AlphaMed Press.

Références

J Oncol Pract. 2018 Jul;14(7):442-446
pubmed: 29932846
QJM. 2013 Jun;106(6):505-15
pubmed: 23447660
Eur J Intern Med. 2015 Dec;26(10):e63-4
pubmed: 26410155
Lancet Oncol. 2011 May;12(5):460-8
pubmed: 21482186
J Geriatr Oncol. 2019 Nov;10(6):884-894
pubmed: 30824222
Ann Oncol. 2013 May;24(5):1306-12
pubmed: 23293115
Rev Med Interne. 2008 Mar;29(3):187-94
pubmed: 17981373
Cancer. 2012 Jul 1;118(13):3377-86
pubmed: 22072065
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
JAMA. 2001 Jun 20;285(23):2987-94
pubmed: 11410097
J Am Geriatr Soc. 1997 Jun;45(6):735-8
pubmed: 9180669
Gut. 1978 Dec;19(12):1105-9
pubmed: 84776
J Am Geriatr Soc. 2010 Mar;58(3):523-6
pubmed: 20158555
Rev Med Interne. 2013 Jun;34(6):337-41
pubmed: 23142127
Ann Oncol. 2007 Aug;18(8):1395-9
pubmed: 17513884
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
J Am Geriatr Soc. 2005 May;53(5):917-8
pubmed: 15877584
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
J Clin Oncol. 2005 Oct 1;23(28):6865-72
pubmed: 16192578
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
PLoS One. 2014 Dec 11;9(12):e115060
pubmed: 25503576
J Clin Oncol. 2014 Aug 20;32(24):2595-603
pubmed: 25071125
Clin Geriatr Med. 2002 Nov;18(4):737-57
pubmed: 12608501
Ann Oncol. 2013 Nov;24(11):2808-13
pubmed: 24061628
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Clin Biochem. 2003 Nov;36(8):585-90
pubmed: 14636871
Age Ageing. 1988 Jul;17(4):227-35
pubmed: 3177082
J Clin Oncol. 2013 Apr 10;31(11):1464-70
pubmed: 23460711
J Pain Symptom Manage. 2000 Aug;20(2):93-103
pubmed: 10989247
J Gerontol A Biol Sci Med Sci. 2015 Sep;70(9):1148-55
pubmed: 25834194
Oncologist. 2020 Jan;25(1):e85-e93
pubmed: 31387952
Cancer Epidemiol. 2016 Feb;40:158-65
pubmed: 26724465
Oncologist. 2011;16(10):1403-12
pubmed: 21914699
Cancer. 1977 Sep;40(3):1348-53
pubmed: 902243
J Clin Oncol. 2016 Jul 10;34(20):2366-71
pubmed: 27185838
JAMA. 2006 Feb 15;295(7):801-8
pubmed: 16478903

Auteurs

Anne-Laure Couderc (AL)

Geriatric and Therapeutic Unit, Internal Medicine, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
PACA West Coordination Unit for Geriatric Oncology (UCOG), Marseille, France.
Etablissement Français du Sang, Anthropologie, Droit, Ethique en Santé, Centre National de la Recherche Scientifique (CNRS), Marseille, France.

Eddy Puchades (E)

Hematology and Cellular Therapy Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.

Patrick Villani (P)

Geriatric and Therapeutic Unit, Internal Medicine, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
PACA West Coordination Unit for Geriatric Oncology (UCOG), Marseille, France.
Etablissement Français du Sang, Anthropologie, Droit, Ethique en Santé, Centre National de la Recherche Scientifique (CNRS), Marseille, France.

Robin Arcani (R)

Geriatric and Therapeutic Unit, Internal Medicine, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
Hematology and Cellular Therapy Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
PACA West Coordination Unit for Geriatric Oncology (UCOG), Marseille, France.

Laure Farnault (L)

Hematology and Cellular Therapy Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.

Aurélie Daumas (A)

Geriatric and Therapeutic Unit, Internal Medicine, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
PACA West Coordination Unit for Geriatric Oncology (UCOG), Marseille, France.
Aix-Marseille Université, Marseille, France.

Anais Courcier (A)

Geriatric and Therapeutic Unit, Internal Medicine, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
PACA West Coordination Unit for Geriatric Oncology (UCOG), Marseille, France.

Laurent Greillier (L)

Multidisciplinary Oncology and Therapeutic Innovations Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
Aix-Marseille Université, Marseille, France.

Fabrice Barlesi (F)

Multidisciplinary Oncology and Therapeutic Innovations Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
Aix-Marseille Université, Marseille, France.

Florence Duffaud (F)

Oncology Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
Aix-Marseille Université, Marseille, France.

Sébastien Salas (S)

Oncology Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
Aix-Marseille Université, Marseille, France.

Régis Costello (R)

Hematology and Cellular Therapy Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
Aix-Marseille Université, Marseille, France.

Gaëtan Gentile (G)

Aix-Marseille Université, Marseille, France.

Vincent Pradel (V)

Public Health Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.

Pierre Suchon (P)

Hematology Laboratory Unit, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
Centre de Recherche en Cardiovasculaire et Nutrition (C2VN), Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (INRAE), INSERM, Marseille, France.

Geoffroy Venton (G)

Hematology and Cellular Therapy Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
Aix-Marseille Université, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH